Reximmune-C2 is under clinical development by GenVivo and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Reximmune-C2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Reximmune-C2 overview
Reximmune-C2 is under development for the treatment of solid tumors including hepatocellular carcinoma, breast and metastatic liver cancer. It is administered through intravenous, intrahepatic and intratumoral routes. The drug candidate comprises of Herpes Simplex Virus (HSV) vector encoding thymidine kinase-m2 and hGM-CSF proteins (HSV-Thymidine Kinase-m2 and hGM-CSF Genes). It is a derivative of Reximmune-C.
For a complete picture of Reximmune-C2’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.